Bausch + Lomb (NYSE:BLCO) Stock Price Down 5.8% – Here’s What Happened

Bausch + Lomb Corporation (NYSE:BLCO) fell 5.8% during mid-day trading on Monday. The stock traded as low as $16.13 and last traded at $16.2990. 154,963 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 414,952 shares. The stock had previously closed at $17.30.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Higher 2026 guidance is the main positive catalyst. Bausch + Lomb said it expects to raise its full-year 2026 guidance, signaling stronger-than-expected operating performance and supporting the subsequent rally in BLCO shares. Bausch + Lomb and Bausch Health announce interim CEO appointment and expected guidance increase
• Positive Sentiment: Thomas J. Appio has taken over as interim CEO. Appio, who also leads parent company Bausch Health and chairs Bausch + Lomb’s board, is expected to provide management continuity while the company evaluates its permanent leadership. Bausch + Lomb CEO Saunders departs and Appio is appointed interim chief
• Neutral Sentiment: Saunders’ exit has now been formally completed. Bausch + Lomb announced that Brent Saunders ceased to serve as a director effective October 12, following his departure as CEO. The move removes uncertainty about the immediate leadership structure but leaves the company with an interim chief executive. Bausch + Lomb announces cessation of Brent Saunders as director
• Negative Sentiment: The sudden CEO transition remains a risk. Saunders’ departure and Appio’s interim status may raise questions about long-term strategy and the timing of a permanent CEO search. That uncertainty contributed to the stock’s initial decline before the guidance update improved sentiment. Bausch + Lomb names Appio interim CEO as Saunders departs

Analyst Ratings Changes

Several brokerages have recently commented on BLCO. Citigroup increased their price objective on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Evercore set a $17.00 target price on Bausch + Lomb in a research report on Monday, July 6th. Weiss Ratings upgraded Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. Leerink Partners assumed coverage on shares of Bausch + Lomb in a report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 price objective on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.46.

Bausch + Lomb Trading Down 1.5%

The company’s fifty day moving average is $17.17 and its two-hundred day moving average is $16.44. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. The company has a market cap of $5.66 billion, a price-to-earnings ratio of -32.97, a P/E/G ratio of 0.50 and a beta of 0.56.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.01). The business had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. On average, research analysts anticipate that Bausch + Lomb Corporation will post 0.81 EPS for the current year.

Insider Buying and Selling at Bausch + Lomb

In related news, Director Eschenbach Andrew C. Von sold 12,500 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the completion of the transaction, the director directly owned 69,792 shares in the company, valued at $1,151,568. The trade was a 15.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at approximately $769,044.18. The trade was a 53.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 71,459 shares of company stock valued at $1,194,370. 1.45% of the stock is currently owned by corporate insiders.

Institutional Trading of Bausch + Lomb

A number of hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP acquired a new position in Bausch + Lomb in the second quarter valued at approximately $1,479,000. Whitebox Advisors LLC boosted its position in Bausch + Lomb by 15.8% in the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after purchasing an additional 150,641 shares in the last quarter. Sei Investments Co. grew its stake in shares of Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after purchasing an additional 69,633 shares during the period. Roxbury Financial LLC acquired a new stake in shares of Bausch + Lomb during the 3rd quarter worth approximately $33,000. Finally, Squarepoint Ops LLC grew its stake in shares of Bausch + Lomb by 31.7% during the 2nd quarter. Squarepoint Ops LLC now owns 24,379 shares of the company’s stock worth $404,000 after purchasing an additional 5,861 shares during the period. Hedge funds and other institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, pharmaceuticals and surgical applications. Its portfolio is intended to address a broad range of eye conditions and support patients, eye-care professionals and surgical specialists.

The company’s vision-care products include contact lenses and contact-lens-care solutions, while its pharmaceutical portfolio includes prescription and over-the-counter treatments for conditions affecting the eyes.